Leo Pharma
Timeline
84 events since 1967Board
Capital
Filings
Financial
Establishments
Address
Other
197019751980198519901995200020052010201520202025
Deadline for the 2026 accounts: 31-07-2027
2026
Reappointment: DELOITTE Bedrijfsrevisoren (statutory auditor)Permanent representative: Pieter-Jan Jean-Baptiste E Van Durme · General meeting of 30-04-20263 points ▸
- General meeting, 30-04-2026
- Auditor reappointment, DELOITTE Bedrijfsrevisoren (statutory auditor)
- Permanent representative, Pieter-Jan Jean-Baptiste E Van Durme
Annual accounts 2025 filed PDFfull format · 86 days before the deadline
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0404780604
Annual accounts 2024 filed PDFfull format · 38 days before the deadline
Amendment of the articles PDF
Appointment: Dilay Kücükkose (director)Resignation: Anders Krüger (director) · Director discharge: Anders Krüger · General meeting of 27-01-20254 points ▸
- General meeting, 27-01-2025
- Director appointment, Dilay Kücükkose
- Director resignation, Anders Krüger
- Director discharge, Anders Krüger
Powers of attorney: Philip Van Den Eynden, Mariana Vieira Falsca and 2 othersBoard meeting of 20-01-20255 points ▸
- Board meeting, 20-01-2025
- Power of attorney, Philip Van Den Eynden
- Power of attorney, Mariana Vieira Falsca
- Power of attorney, Martine Debecker
- Power of attorney, Antoine Bodereau
2024
Liquidity more than doubled current ratio 4.40 The current ratio rises from 1.97 to 4.40. Short-term debt falls from €8.8m to €2.7m.
Annual accounts 2023 filed PDFfull format · 71 days before the deadline
Resignation: Jannie Holm (director)Appointment: Anders Krüger (director) · General meeting of 10-01-20245 points ▸
- General meeting, 10-01-2024
- Director resignation, Jannie Holm
- Director appointment, Anders Krüger
- Board composition, Hilda De Swaef (director)
- Board composition, Anders Krüger (director)
2023
Back to profit net €793,396 The net result is €793,396, after one loss-making year.
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)Permanent representative: Pieter-Jan Van Durme · General meeting of 31-05-20236 points ▸
- Board meeting, 22-05-2023
- Power of attorney, David Wilson
- Power of attorney, Mariana Vieira Faísca
- General meeting, 31-05-2023
- Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
- Permanent representative, Pieter-Jan Van Durme
- The deed holds 1 more point.
Annual accounts 2022 filed PDFfull format · 56 days before the deadline
2022
Weakest financial year net -€167,620 The net result drops to -€167,620, the lowest from 2006 to 2025. It recovers the following year.
Permanent representatives: Pieter-Jan Van Durme and Gert VanheesBoard meeting of 19-08-20223 points ▸
- Board meeting, 19-08-2022
- Permanent representative, Pieter-Jan Van Durme
- Permanent representative, Gert Vanhees
Powers of attorney: Lucy Megens, David Wilson and Philip Van den EyndenBoard meeting of 15-07-20224 points ▸
- Board meeting, 15-07-2022
- Power of attorney, Lucy Megens
- Power of attorney, David Wilson
- Power of attorney, Philip Van den Eynden
Annual accounts 2021 filed PDFfull format · 3 days before the deadline
2 directors appointed, 1 resignationResignation: Michael Grue · Appointments: Jannie Holm and Hilda De Swaef · Director discharge: Michael Grue · General meeting of 17-03-20227 points ▸
- General meeting, 17-03-2022
- Director resignation, Michael Grue
- Director discharge, Michael Grue
- Director appointment, Jannie Holm
- Director appointment, Hilda De Swaef
- Board composition, Jannie Holm (director)
- Board composition, Hilda De Swaef (director)
- The deed holds 2 more points.
Resignation: Catherine Mazzacco (director)Director discharge: Catherine Mazzacco · General meeting of 20-12-20214 points ▸
- General meeting, 20-12-2021
- Director resignation, Catherine Mazzacco
- Director discharge, Catherine Mazzacco
- Board composition, Michael Grue (director)
- The deed holds 1 more point.
2021
1 director appointed, 2 resignations, 1 statutory auditor reappointedReappointment: Deloitte Bedrijfsrevisoren CV (statutory auditor) · Resignations: Kim Kjøller and Anders Kronborg · Appointment: Michael Grue · General meeting of 06-07-20218 points ▸
- General meeting, 30-06-2020
- Auditor reappointment, Deloitte Bedrijfsrevisoren CV (statutory auditor)
- General meeting, 06-07-2021
- Director resignation, Kim Kjøller
- Director resignation, Anders Kronborg
- Director appointment, Michael Grue
- Board composition, Michael Grue (director)
- Board composition, Catherine Thérése Jeanne Mazzacco (director)
Annual accounts 2020 filed PDFfull format · 8 days before the deadline
2020
Boekjaar“controle van het bestuur of deelneming aan bestuur van elke onderneming, in voorkomend geval door mandaat…” (deed in Dutch) · General meeting of 20-10-20204 points ▸
- General meeting, 20-10-2020
- Purpose change, “controle van het bestuur of deelneming aan bestuur van elke onderneming, in voorkomend geval door mandaat zoals bestuurder, lid raad van toezicht of directieraa…” (deed in Dutch)
- Capital, €272,682.87, 55,992 shares
- Registered office clause, Duwijckstraat 17
- The deed holds 2 more points.
Change of role: De Swaef, from director to day-to-day managerGeneral meeting of 18-08-20204 points ▸
Annual accounts 2019 filed PDFfull format · 18 days before the deadline
2019
Annual accounts 2018 filed PDFfull format · 121 days late
Resignation: Aabo GITTE (director)Appointment: Catherine Thérése Jeanne MAZZACCO (director) · General meeting of 10-10-20193 points ▸
- General meeting, 10-10-2019
- Director resignation, Aabo GITTE
- Director appointment, Catherine Thérése Jeanne MAZZACCO
2018
Annual accounts 2017 filed PDFfull format · 59 days late
Resignations & appointments2 points ▸
- Management decision, 08-08-2018
- Power of attorney, Lucy Megens
- The deed holds 2 more points.
New statutory auditorDeloitte Bedrijfsrevisoren BCVBA appointed, PricewaterhouseCoopers Bedrijfsrevisoren BCVBA resigned · General meeting of 30-10-20173 points ▸
- General meeting, 30-10-2017
- Auditor resignation, PricewaterhouseCoopers Bedrijfsrevisoren BCVBA (statutory auditor)
- Auditor appointment, Deloitte Bedrijfsrevisoren BCVBA (statutory auditor)
- The deed holds 1 more point.
2017
Annual accounts 2016 filed PDFfull format · 95 days before the deadline
2016
Resignation: Kristian Merser (director)Appointment: Kim Kjøller (director) · General meeting of 01-09-20163 points ▸
- General meeting, 01-09-2016
- Director resignation, Kristian Merser
- Director appointment, Kim Kjøller
2 directors appointed, 3 resignations, 1 reappointment, 1 statutory auditor reappointedReappointments: Gitte Aabo (director and chair of the board) and PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor) · Appointments: Kristian Merser and Anders Kronborg · Resignations: Lars Olsen, Lars Enghave Minor and Hilde De Swaef · General meeting of 01-04-20168 points ▸
- General meeting, 01-04-2016
- Director reappointment, Gitte Aabo (director and chair of the board)
- Director appointment, Kristian Merser
- Director appointment, Anders Kronborg
- Director resignation, Lars Olsen
- Director resignation, Lars Enghave Minor
- Director resignation, Hilde De Swaef
- Auditor reappointment, PricewaterhouseCoopers Bedrijfsrevisoren
Annual accounts 2015 filed PDFfull format · 103 days before the deadline
2015
Annual accounts 2014 filed PDFfull format · 86 days before the deadline
2014
Annual accounts 2013 filed PDFfull format · 84 days before the deadline
2013
Reappointment: BCVBA PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)Permanent representative: Bart Vari Gompel · General meeting of 11-04-20133 points ▸
- General meeting, 11-04-2013
- Auditor reappointment, BCVBA PricewaterhouseCoopers Bedrijfsrevisoren
- Permanent representative, Bart Vari Gompel
Annual accounts 2012 filed PDFfull format · 100 days before the deadline
2012
2 directors appointed, 2 resignationsResignations: Jens Bo Olesen and Tore Waeborg (managing director) · Appointments: Lars Enghave Minor and Hilda de Swaef (managing director) · Mandate compensation: Lars Enghave Minor · General meeting of 15-06-201216 points ▸
- General meeting, 15-06-2012
- Director resignation, Jens Bo Olesen
- Director resignation, Tore Waeborg
- Director appointment, Lars Enghave Minor
- Director appointment, Hilda de Swaef
- Mandate compensation, Lars Enghave Minor
- Mandate compensation, Hilda de Swaef, mentioned twice in the deed
- Board composition, Gitte Pugholm Aabo (director)
- Board composition, Lars Olsen (director)
- Board composition, Lars Enghave Minor (director)
- Board composition, Hilda de Swaef (director)
- Power of attorney, Tom Swinnen, mentioned twice in the deed
- Power of attorney, Michel Bonne, mentioned twice in the deed
- Board meeting, 15-06-2012
- Director resignation, Tore Waeborg (managing director)
- Director appointment, Hilda de Swaef (managing director)
Annual accounts 2011 filed PDFfull format · 70 days before the deadline
2011
Annual accounts 2010 filed PDFfull format · 24 days late
Amendment of the articlesCapital of €272,682.87, 55,992 shares · General meeting of 18-01-20113 points ▸
- General meeting, 18-01-2011
- Capital, €272,682.87, 55,992 shares
- Board resolution, 25-02-2010
- The deed holds 1 more point.
New statutory auditorPricewaterhouseCoopers Bedrijfsrevisoren appointed, BDO Bedrijfsrevisoren BCVBA resigned · General meeting of 27-09-20103 points ▸
- General meeting, 27-09-2010
- Director resignation, BDO Bedrijfsrevisoren BCVBA (statutory auditor)
- Auditor appointment, PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
- The deed holds 1 more point.
2010
Annual accounts 2009 filed PDFfull format · 31 days late
Registered office moved from Wilrijk to LierNew registered office: Duijckstraat 17, 2500 Lier · Previous registered office: Sneeuwbeslaan 20, 2610 Wilrijk (België) · Board meeting of 25-02-20102 points ▸
- Board meeting, 25-02-2010
- Registered-office move, Duijckstraat 17, 2500 Lier
3 directors appointed, 2 resignations, 4 reappointmentsAppointments: Tore Waeborg (managing director), Hilde De Swaet (director) and Lars Olsen · Reappointments: Gitte Aabo, Jens Bo Olesen, Tore Waeborg and Ger Schoor · Resignations: Ger Schoor and Jens Bo Olesen · Board meeting of 25-02-201011 points ▸
- Board meeting, 25-02-2010
- General meeting, 25-02-2010
- Director appointment, Tore Waeborg (managing director)
- Director appointment, Hilde De Swaet (director (executive))
- Director reappointment, Gitte Aabo
- Director reappointment, Jens Bo Olesen
- Director reappointment, Tore Waeborg
- Director reappointment, Ger Schoor
- Director appointment, Lars Olsen
- Director resignation, Ger Schoor
- Director resignation, Jens Bo Olesen
2009
Equity above €10m equity €11.7m ▲24% With a profit in every financial year since 2006, equity grows to €11.7m.
Annual accounts 2008 filed PDFfull format · 35 days before the deadline
2008
1 director resigning, 4 reappointments, 1 statutory auditor reappointedResignation: Ernst Lunding · Reappointments: Gitte Aabo, Bo Olesen, Ger Schoor, Tore Waeborg and BDO Bedrijfsrevisoren (statutory auditor) · Permanent representative: Jan Vercauteren · General meeting of 04-03-20089 points ▸
- General meeting, 04-03-2008
- Director resignation, Ernst Lunding
- Director reappointment, Gitte Aabo
- Director reappointment, Bo Olesen
- Director reappointment, Ger Schoor
- Director reappointment, Tore Waeborg
- Mandate compensation, LEO PHARMA
- Auditor reappointment, BDO Bedrijfsrevisoren
- Permanent representative, Jan Vercauteren (company auditor)
Annual accounts 2007 filed PDFfull format · 27 days late
2 directors appointed, 3 reappointmentsReappointments: Ernst Lunding, Jens Bo Olesen and Ger Schoor · Appointments: Gitte Aabo and Tore Waeborg · General meeting of 06-03-20077 points ▸
- General meeting, 06-03-2007
- Director reappointment, Ernst Lunding
- Director reappointment, Jens Bo Olesen
- Director reappointment, Ger Schoor
- Director appointment, Gitte Aabo
- Director appointment, Tore Waeborg
- Number of directors, 5
- The deed holds 1 more point.
2007
Highest result from 2006 to 2025 net €3.1m ▲50.9% The net result of €3.1m is the highest of those years.
Equity above €5m equity €6.6m ▲86.9% With a profit in every financial year since 2006, equity grows to €6.6m.
Annual accounts 2006 filed PDFfull format · 35 days before the deadline
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
2003
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2001
Annual accounts 2000 filed PDFfull format
2000
Annual accounts 1999 filed PDFfull format
1999
Annual accounts 1998 filed PDFfull format
1998
Annual accounts 1997 filed PDFfull format
1997
Annual accounts 1996 filed PDFfull format
1996
Annual accounts 1995 filed PDFfull format
1995
Annual accounts 1994 filed PDFfull format
1994
Annual accounts 1993 filed PDFfull format
1993
Annual accounts 1992 filed PDFfull format
1992
Annual accounts 1991 filed PDFfull format
1991
Annual accounts 1990 filed PDFfull format
1990
Annual accounts 1989 filed PDFfull format
1989
Annual accounts 1988 filed PDFfull format
1988
Annual accounts 1987 filed PDFfull format
1987
Annual accounts 1986 filed PDFfull format
1986
Annual accounts 1985 filed PDFfull format
1985
Annual accounts 1984 filed PDFfull format
1984
Annual accounts 1983 filed PDFunclassified schema
1983
Annual accounts 1982 filed PDFunclassified schema
1982
Annual accounts 1981 filed PDFunclassified schema
1981
Annual accounts 1980 filed PDFunclassified schema
1980
Annual accounts 1979 filed PDFunclassified schema
1979
Annual accounts 1978 filed PDFunclassified schema
1978
Annual accounts 1977 filed PDFunclassified schema
1971
First establishment Duwijckstraat 17, Lier
1967
Incorporation KBO
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Leo Pharma was incorporated on 1 April 1967.1 The registered office was moved to Lier in 2010.2 The board currently has 2 members. Hilda De Swaef has served longest, since 2022.3 Turnover grew from €27.0m in 2018 to €32.1m in 2025 and headcount from 30.9 to 21.7 full-time equivalents.4